Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Laboratorios Silanes S A De C V is currently navigating 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners, showing a concentration of work among the assigned staff. The portfolio is further organized into 2 distinct art units, which suggests the company's innovations fall into related technical categories within the broader pharmaceutical field.
The busiest examiner for this portfolio is TCHERKASSKAYA, OLGA V, who is responsible for 2 pending office actions. This means that one examiner is handling 2 of the company's 4 pending office actions, making her a key figure in the company's current prosecution efforts. The remaining cases are split between the other 3 distinct examiners.
With 4 pending office actions and a limited number of examiners, the company experiences more examiner overlap than portfolios where each examiner handles a single case. This concentration in 2 distinct art units and the primary role of TCHERKASSKAYA, OLGA V suggests that the company's legal strategy should prioritize understanding the specific preferences of this busiest examiner.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 2 | 55.4% | +46.2% |
| ROSENTHAL, ANDREW S | 1 | 51.8% | +38.7% |
| BURKETT, DANIEL JOHN | 1 | 62.6% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028625 | PHARMACEUTICAL COMBINATIONS OF STATINS AND FIBRATES FOR THE TREATMENT AND PREVENTION OF HYPERLIPIDEMIAS AND CARDIOVASCULAR DISEASE | TCHERKASSKAYA, OLGA V | 34d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18255244 | STABLE COATED SOLID PHARMACEUTICAL COMPOSITION OF AN OPIOID ANALGESIC AND AN ANTI-EPILEPTIC FOR PAIN | TCHERKASSKAYA, OLGA V | 21d |
| 18255205 | PHARMACEUTICAL COMBINATION OF A CORTICOSTEROID AND AN ANTIHISTAMINE FOR THE TREATMENT AND CONTROL OF THE INFLAMMATORY COMPONENT OF ALLERGIC PROCESSES | BURKETT, DANIEL JOHN | 22d |
| 18028625 | PHARMACEUTICAL COMBINATIONS OF STATINS AND FIBRATES FOR THE TREATMENT AND PREVENTION OF HYPERLIPIDEMIAS AND CARDIOVASCULAR DISEASE | TCHERKASSKAYA, OLGA V | 34d |
| 18906605 | CELECOXIB - ACETAMINOPHEN COMBINATION OF IMPROVED STABILITY AND PREPARATION PROCEDURE | ROSENTHAL, ANDREW S | — |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18906605 | CELECOXIB - ACETAMINOPHEN COMBINATION OF IMPROVED STABILITY AND PREPARATION PROCEDURE | ROSENTHAL, ANDREW S | — | §103Other | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18255244 | STABLE COATED SOLID PHARMACEUTICAL COMPOSITION OF AN OPIOID ANALGESIC AND AN ANTI-EPILEPTIC FOR PAIN | TCHERKASSKAYA, OLGA V | 1615 | §103 | Non-Final OA | 21d | Pending | May 31, 2023 |
| 18255205 | PHARMACEUTICAL COMBINATION OF A CORTICOSTEROID AND AN ANTIHISTAMINE FOR THE TREATMENT AND CONTROL OF THE INFLAMMATORY COMPONENT OF ALLERGIC PROCESSES | BURKETT, DANIEL JOHN | 1624 | §112 | Non-Final OA | 22d | Pending | May 31, 2023 |
| 18028625 | PHARMACEUTICAL COMBINATIONS OF STATINS AND FIBRATES FOR THE TREATMENT AND PREVENTION OF HYPERLIPIDEMIAS AND CARDIOVASCULAR DISEASE | TCHERKASSKAYA, OLGA V | 1615 | §103§112 | Non-Final OA | 34d | Pending | Mar 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial